LISTEN: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring

Are megamergers bad for business? Is it time for biotech’s biggest gathering to find a new home? And can a “need” be anything but “unmet”?

We discuss all that and more on 2019’s first episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Matthew Herper joins us to break down Bristol-Myers Squibb’s plot to acquire Celgene for $74 billion and its implications for the industry at large. Then we talk about what to expect at next week’s J.P. Morgan Healthcare Conference and dig into whether biotech’s biggest meeting has outgrown its environs. Finally, veteran CEO whisperer and W20 Group Global Practice Leader Mike Huckman stops by to count down the 10 most egregious bits of corporate jargon spouted by biotech executives.